Full Text View
Tabular View
Contacts and Locations
No Study Results Posted
Related Studies
Stimulant Abuser Groups to Engage in 12-Step (STAGE-12)
This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA), January 2009
Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
University of Washington
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00573183
  Purpose

The purpose of this study is to determine whether a combined group and individual 12-Step facilitative intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12), improves substance -related outcomes.


Condition Intervention Phase
Stimulant Abuse or Dependence
Behavioral: Twelve Step Facilitation (TSF)
Phase III

U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Reduction in percent of days of stimulant use [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Increased attendance at 12-step meetings [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: January 2008
Estimated Study Completion Date: August 2010
Estimated Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
STAGE-12: Experimental Behavioral: Twelve Step Facilitation (TSF)
The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
Treatment as Usual: No Intervention

Detailed Description:

This protocol is to evaluate the degree to which a combined group and individual 12-Step facilitative intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12), improves substance -related outcomes compared to treatment as usual (TAU) without STAGE-12 among stimulant abusers. The primary objective is to evaluate reduction in percent of days of stimulant use as measured by self-report. Secondary objectives include evaluating reduction in percent days of use of other substances, the degree to which STAGE-12 increases involvement in 12-step activities and attendance at 12-step meetings, and the extent to which such 12 -step involvement and meeting attendance mediate substance use outcomes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • seeking outpatient treatment for stimulant abuse or dependence
  • current diagnosis of stimulant abuse or dependence
  • willing to participate in the protocol

Exclusion Criteria:

  • not sufficiently medically or psychiatrically stable
  • pending legal action that would inhibit their participation in the study
  • in need of detoxification from opiates
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573183

Contacts
Contact: Anthony Floyd, Ph.D. 206-543-1285 asfloyd@u.washington.edu

Locations
United States, Florida
Gateway Community Services Recruiting
Jacksonville, Florida, United States, 32211
Contact: Christine Neuenfeldt     904-721-9958     cneuenfeldt@gatewaycommunity.com    
United States, Hawaii
Hina Mauka Kaneohe Rehabilitation Services Recruiting
Kaneohe, Hawaii, United States, 96744
Contact: Nicole Baumhofer     808-236-2600     nbaumhofer@hinamauka.org    
United States, Ohio
Maryhaven, Inc. Recruiting
Columbus, Ohio, United States, 43207
Contact: Jessica Rich     614-324-5430     jrich@maryhaven.com    
United States, Oregon
ChangePoint, Inc. Recruiting
Portland, Oregon, United States, 97233
Contact: Chris Botero     503-419-2659     cbotero@changepointinc.com    
Willamette Family Treatment Services Recruiting
Eugene, Oregon, United States, 97402
Contact: Davina Jones     541-343-2993     davinaj@wfts.org    
United States, Pennsylvania
Addiction Medicine Services (WPIC) Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Mary Elyse Kaye     412-246-6467     kayeme@upmc.edu    
United States, South Carolina
Dorchester Alcohol and Drug Commission Recruiting
Summerville, South Carolina, United States, 29483
Contact: Ashley Morrill     843-871-4790     asfloyd@u.washington.edu    
United States, Texas
Nexus Recovery Center Recruiting
Dallas, Texas, United States, 75228
Contact: Aubrey Hopkins     817-569-4278     aubrey.hopkins@utsouthwestern.edu    
United States, Washington
Recovery Centers of King County Recruiting
Seattle, Washington, United States, 98122
Contact: Jessica DiCenzo     206-568-8227     jdicenzo@rckc.org    
Evergreen Manor, Inc. Recruiting
Everett, Washington, United States, 98134
Contact: Danielle Shandera     425-493-5320     dshandera@evergreenmanor.org    
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: Dennis Donovan, Ph.D. University of Washington
Principal Investigator: Dennis Daley, Ph.D. Western Psychiatric Institute and Clinic
  More Information

No publications provided

Responsible Party: University of Washington ( Dennis Donovan )
Study ID Numbers: NIDA-CTN-0031, U10 DA13714
Study First Received: December 13, 2007
Last Updated: January 28, 2009
ClinicalTrials.gov Identifier: NCT00573183  
Health Authority: United States: Federal Government

ClinicalTrials.gov processed this record on February 12, 2009